Japanese Government Procurement

Ministry of Defense - Notice of Procurement (Goods & Services)Infliximab (genetical recombination) for intravenous infusion 100㎎ (100㎎×1vial/case) 807 cases,and 41 other contracts

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Jan 31, 2022
Type of notice Notice of Procurement (Goods & Services)
Procurement entity Ministry of Defense - Saitama
Classification
0004 Medical & Pharmaceutical Products
0032 Medical Supplies
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : Takahiro Yoshida, Department of Finance, National Defense Medical College
⑵ Classification of the products to be procured : 4, 32
⑶ Nature and quantity of the products to be purchased :
①-1 Infliximab (genetical recombination) for intravenous infusion 100㎎ (100㎎×1vial/case) 807 cases
①-2 Pembrolizumab (genetical recombination) intravenous infusion 100㎎ (100㎎ 4mL×1vial/case) 212 cases
①-3 Vedolizumab (genetical recombination) for intravenous infusion 300㎎ (300㎎×1vial/case) 169 cases
①-4 Mepolizumab (genetical recombination) subcutaneous injection 100㎎ (100㎎×1pen/case) 217 cases
①-5 Ustekinumab (genetical recombination) subcutaneous injection 45㎎ (45㎎×1syringe/case) 101 cases
①-6 Denosumab (genetical recombination) subcutaneous injection 120㎎ (120㎎×1vial/case) 628 cases
①-7 Bevacizumab (genetical recombination) for intravenous infusion 400㎎/16mL (400㎎ 16mL×1vial/case) 208 cases
①-8 Tocilizumab (genetical recombination) for intravenous infusion 100㎎ (200㎎ 10mL×1vial/case) 656 cases
①-9 Letermovir tablets 240㎎ (240㎎×14tablets/case) 98 cases
①-10 Leuprorelin Acetate for injection kit 11.25㎎ (11.25㎎×1kit/case) 362 cases
①-11 Thrombomodulin Alfa (genetical recombination) for intravenous infusion 12800 units (12800units×10 vials/case) 45 cases
①-12 Rituximab (genetical recombination) intravenous infusion 500㎎ 50mL (500㎎ 50mL×1vial/case) 129 cases
①-13 Polyethylene Glycol Treated Human Normal Immunoglobulin 10% intravenous injection 5g 50mL (5g 50mL×1vial/case) 501 cases
①-14 Aflibercept (genetical recombination) solution kit for intravitreal injection 40㎎/mL (2㎎×1kit/case) 119 cases
①-15 Sugammadex intravenous 200㎎ (200㎎ 2mL×10vials/case) 176 cases
①-16 Pegfilgrastim (genetical recombination) subcutaneous injection 3.6㎎ (3.6㎎×1syringe/case) 145 cases
②-1 Irradiated Whole Blood, Leukocytes Reduced, NISSEKI 1 (Japanese Red Cross Society Derived from 200mL donation) 1 bag
②-2 Irradiated Whole Blood, Leukocytes Reduced, NISSEKI 2 (Japanese Red Cross Society Derived from 400mL donation) 1 bag
②-3 Irradiated Red Blood Cells, Leukocytes Reduced, NISSEKI 1 (Japanese Red Cross Society Derived from 200mL donation) 31 bags
②-4 Irradiated Red Blood Cells, Leukocytes Reduced, NISSEKI 2 (Japanese Red Cross Society Derived from 400mL donation) 6,000 bags
②-5 Irradiated Washed Red Cells, Leukocytes Reduced, NISSEKI 1 (Japanese Red Cross Society Derived from 200mL donation) 1 bag
②-6 Irradiated Washed Red Cells, Leukocytes Reduced, NISSEKI 2 (Japanese Red Cross Society Derived from 400mL donation) 1 bag
②-7 Frozen Thawed Red Cells, Leukocytes Reduced, NISSEKI 1 (Japanese Red Cross Society Derived from 200mL donation) 1 bag
②-8 Frozen Thawed Red Cells, Leukocytes Reduced, NISSEKI 2 (Japanese Red Cross Society Derived from 400mL donation) 1 bag
②-9 Irradiated Blood for Exchange Transfusion, Leukocytes Reduced, NISSEKI 1 (Japanese Red Cross Society RBC derived from 200mL of whole blood plus approx. 60mL of plasma/bag) 1 bag
②-10 Irradiated Blood for Exchange Transfusion, Leukocytes Reduced, NISSEKI 2 (Japanese Red Cross Society RBC derived from 400mL of whole blood plus approx. 120mL of plasma/bag) 1 bag
②-11 Fresh Frozen Plasma, Leukocytes Reduced, NISSEKI 120 (Japanese Red Cross Society Derived from 200mL donation) 5 bags
②-12 Fresh Frozen Plasma, Leukocytes Reduced, NISSEKI 240 (Japanese Red Cross Society Derived from 400mL donation) 2,858 bags
②-13 Fresh Frozen Plasma, Leukocytes Reduced, NISSEKI 480 (Japanese Red Cross Society 480mL/bag) 387 bags
②-14 Irradiated Platelet Concentrate, Leukocytes Reduced, NISSEKI 5 (Japanese Red Cross Society≧1.0×1011 PLTs/bag) 3 bags
②-15 Irradiated Platelet Concentrate, Leukocytes Reduced, NISSEKI 10 (Japanese Red Cross Society≧2.0×1011 PLTs/bag) 2,390 bags
②-16 Irradiated Platelet Concentrate, Leukocytes Reduced, NISSEKI 15 (Japanese Red Cross Society≧3.0×1011 PLTs/bag) 16 bags
②-17 Irradiated Platelet Concentrate, Leukocytes Reduced, NISSEKI 20 (Japanese Red Cross Society≧4.0×1011 PLTs/bag) 31 bags
②-18 Irradiated Platelet Concentrate HLA, Leukocytes Reduced, NISSEKI 10 (Japanese Red Cross Society≧2.0×1011 PLTs/bag) 100 bags
②-19 Irradiated Platelet Concentrate HLA, Leukocytes Reduced, NISSEKI 15 (Japanese Red Cross Society≧3.0×1011 PLTs/bag) 5 bags
②-20 Irradiated Platelet Concentrate HLA, Leukocytes Reduced, NISSEKI 20 (Japanese Red Cross Society≧4.0×1011 PLTs/bag) 3 bags
②-21 Irradiated Washed Platelet Concentrate, Leukocytes Reduced, NISSEKI (Japanese Red Cross Society≧2.0×1011 PLTs/bag) 128 bags
②-22 Irradiated Washed Platelet Concentrate HLA, Leukocytes Reduced, NISSEKI (Japanese Red Cross Society≧2.0×1011 PLTs/bag) 24 bags
②-23 Albumin Behring 20% I.V.lnjection 10.0g/50㎖ (CSL Behring Albumin Behring 20% I.V.lnjection 10.0g/50㎖) 1,845 I.V.lnjection
②-24 Albumin 5% I.V.lnjection 12.5g/250㎖ (CSL Behring Albumin 5% I.V.lnjection 12.5g/250㎖) 1,380 I.V.lnjection
②-25 Sekijuji Albumin 25% I.V. 12.5g/50㎖ (Japanese Blood Products Organization Sekijuji Albumin 25% I.V. 12.5g/50㎖) 22 I.V.lnjection
②-26 TEMCELL HS Inj (JCR Pharmaceuticals TEMCELL HS Inj) 1 bags
⑷ Derivery Period : From 1, April, 2022 through 31, March, 2023
⑸ Delivery Place : National Defense Medical College Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
① not come under Article 70 of the Cabinet Order concerning the Budget, Auditing and Accounting. Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause.
② not come under Article 71 of the Cabinet Order concerning the Budget, Auditing and Accounting.
③ have Grade A, B or C in the "Sale" in the Kanto and Koushinetsu area in terms of the qualification for participating in tenders by Ministry of Defense (Single qualification for every ministry and agency) in the fiscal years 2019, 2020 and 2021.
④ prove to have obtained license for Selling a medical instrument in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices
⑤ prove to have the ability to deliver the products. required by this notice, on the date and to the place specified by the Official in charge of disbursement of the procuring entity.
⑥ The person who is not being under suspension of nomination by Director General for Health and Medicine, Director General, Bureau of Defence Policy, Director General, Acquisition Technology and Logistics Agency, or by National Defense Medical College President
⑺ Time-limit for tender
① 17 : 00 24 March 2022 in case of by mail, 10 : 00 25 March 2022 in case of by hand.
② 17 : 00 24 March 2022 in case of by mail, 10 : 15 25 March 2022 in case of by hand.
⑻ Contact point for the notice : Hiroaki Takashita. Accounting Division, National Defense Medical College 3-2 Namiki Tokorozawa City Saitama 359-8513 Japan. TEL 04-2995-1309